- Home
- ELUT vs STRO Comparison
ELUT vs STRO Comparison
Compare ELUT & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELUT
- STRO
- Stock Information
- Founded
- ELUT 2015
- STRO 2003
- Country
- ELUT United States
- STRO United States
- Employees
- ELUT N/A
- STRO N/A
- Industry
- ELUT Medical Specialities
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ELUT Health Care
- STRO Health Care
- Exchange
- ELUT Nasdaq
- STRO Nasdaq
- Market Cap
- ELUT 94.0M
- STRO 77.7M
- IPO Year
- ELUT 2020
- STRO 2018
- Fundamental
- Price
- ELUT $1.78
- STRO $0.90
- Analyst Decision
- ELUT Strong Buy
- STRO Hold
- Analyst Count
- ELUT 2
- STRO 7
- Target Price
- ELUT $8.00
- STRO $5.47
- AVG Volume (30 Days)
- ELUT 43.3K
- STRO 1.2M
- Earning Date
- ELUT 05-08-2025
- STRO 05-08-2025
- Dividend Yield
- ELUT N/A
- STRO N/A
- EPS Growth
- ELUT N/A
- STRO N/A
- EPS
- ELUT N/A
- STRO N/A
- Revenue
- ELUT $23,711,000.00
- STRO $66,434,000.00
- Revenue This Year
- ELUT $37.67
- STRO N/A
- Revenue Next Year
- ELUT $63.22
- STRO N/A
- P/E Ratio
- ELUT N/A
- STRO N/A
- Revenue Growth
- ELUT N/A
- STRO N/A
- 52 Week Low
- ELUT $1.61
- STRO $0.52
- 52 Week High
- ELUT $5.24
- STRO $5.17
- Technical
- Relative Strength Index (RSI)
- ELUT 41.19
- STRO 48.67
- Support Level
- ELUT $1.61
- STRO $0.86
- Resistance Level
- ELUT $1.89
- STRO $0.99
- Average True Range (ATR)
- ELUT 0.13
- STRO 0.09
- MACD
- ELUT 0.02
- STRO -0.00
- Stochastic Oscillator
- ELUT 31.22
- STRO 57.19
About ELUT Elutia Inc.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.